Literature DB >> 25192491

Serum parathyroid hormone as a potential novel biomarker of coronary heart disease.

Fa-Li Zhao1, Ying-Zhong Zhang, Guo-Xia Tai, Yu Wang, Qiu-Hui Tong, Lu Fu.   

Abstract

OBJECTIVE: This study aimed to evaluate the relationships between serum parathyroid hormone (PTH) and coronary heart disease (CHD).
METHODS: From July 2011 to February 2013, a total of 79 CHD patients and 94 normal control patients with ages ranging from 25 to 79 years were included in this study. Serum PTH level and common risk factors of CHD (age, gender, cholesterol, glycosylated hemoglobin [HbA1c], blood pressure [BP], history of diabetes, smoking, and body mass index) were investigated. Pearson's correlation and multiple regression analyses were used to evaluate the relationships between serum PTH level and CHD risk factors. All statistical analyses were performed using the SPSS 18.0 software.
RESULTS: RESULTS from Pearson's correlation analysis indicated that age, systolic blood pressure (SBP), diastolic blood pressure (DBP), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), HbA1c, history of smoking, and serum PTH level were risk factors for CHD (all p<0.05). Serum PTH levels were positively correlated with DBP (r=0.256, p=0.010) and HbA1c (r=0.223, p=0.003), while not being related to other risk factors of CHD (all p>0.05). Multiple linear regression analysis showed that SBP, DBP, LDL-c, and HDL-c may be important determinants of CHD (all p<0.05). Further, serum PTH level is also an independent risk factor for CHD (p<0.001).
CONCLUSION: Our results provide evidence that serum PTH level may be involved in the pathogenesis of CHD. Thus, PTH could be used as an important biomarker in the diagnosis of CHD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25192491     DOI: 10.1089/gtmb.2014.0074

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  1 in total

Review 1.  Personalized Management of Cardiovascular Disorders.

Authors:  Kewal K Jain
Journal:  Med Princ Pract       Date:  2017-09-11       Impact factor: 1.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.